Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

36.46USD
14 Dec 2017
Change (% chg)

$-0.18 (-0.49%)
Prev Close
$36.64
Open
$36.70
Day's High
$36.88
Day's Low
$36.34
Volume
4,834,482
Avg. Vol
4,871,893
52-wk High
$36.88
52-wk Low
$30.90

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $217,327.41
Shares Outstanding(Mil.): 5,960.71
Dividend: 0.32
Yield (%): 3.51

Financials

  Industry Sector
P/E (TTM): -- 32.50 16.04
EPS (TTM): -- -- --
ROI: -- 15.11 35.70
ROE: -- 16.59 15.40

Pfizer's Xeljanz gets FDA nod as joint disease treatment

U.S. drugmaker Pfizer Inc said on Thursday the U.S. Food and Drug Administration (FDA) approved two doses of its drug Xeljanz for treatment of a joint disease.

Dec 14 2017

UPDATE 1-Pfizer's Xeljanz gets FDA nod as joint disease treatment

Dec 14 U.S. drugmaker Pfizer Inc said on Thursday the U.S. Food and Drug Administration (FDA) approved two doses of its drug Xeljanz for treatment of a joint disease.

Dec 14 2017

Pfizer's Xeljanz gets FDA nod as joint disease treatment

Dec 14 U.S. drugmaker Pfizer Inc said on Thursday the United States Food and Drug Administration (FDA) approved two doses of its drug Xeljanz for the treatment of a joint disease.

Dec 14 2017

BRIEF-Pfizer Announces FDA Approval Of Xeljanz® And Xeljanz® Xr For Treatment Of Active Psoriatic Arthritis

* PFIZER ANNOUNCES FDA APPROVAL OF XELJANZ® (TOFACITINIB) AND XELJANZ® XR FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS

Dec 14 2017

BRIEF-Pfizer Announces Pricing Terms Of Private Exchange Offer For 6.500 PCT Notes Due 2038

* PFIZER INC ANNOUNCES PRICING TERMS OF PRIVATE EXCHANGE OFFER FOR ITS 6.500 PER CENT. NOTES DUE 2038 OPEN TO CERTAIN INVESTORS AND RELATED TENDER OFFER OPEN TO ALL INVESTORS

Dec 14 2017

BRIEF-Pfizer Initiates Phase 3 Program For Pf-04965842, A Jak1 Inhibitor In Development For Moderate-To-Severe Atopic Dermatitis

* PFIZER INITIATES PHASE 3 PROGRAM FOR PF-04965842, A JAK1 INHIBITOR IN DEVELOPMENT FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS

Dec 14 2017

Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval

The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday.

Dec 13 2017

Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval

Dec 13 The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday.

Dec 13 2017

BRIEF-FDA Approves Pfizer's New Biosimilar To Remicade

* PFIZER INC - UNITED STATES FOOD AND DRUG ADMINISTRATION HAS APPROVED IXIFI AS A BIOSIMILAR TO REMICADE Source text for Eikon: Further company coverage:

Dec 13 2017

BRIEF-Cellectis, Servier And Pfizer Present Preliminary Data From Two UCART19 Phase I Studies

* SERVIER AND PFIZER PRESENT PRELIMINARY DATA FROM UCART19 PHASE I STUDIES IN ADULT AND PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

Dec 13 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.08 +0.43
Novartis AG (NOVN.S) CHF83.85 --
Merck & Co., Inc. (MRK.N) $56.01 -0.90
Roche Holding Ltd. (ROG.S) CHF241.70 0.00
Roche Holding Ltd. (RO.S) CHF242.50 -0.70
Abbott Laboratories (ABT.N) $55.38 +0.65
Bayer AG (BAYGn.DE) €106.50 +1.40
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €73.77 -0.89
AstraZeneca plc (AZN.L) 4,881.00 -3.50

Earnings vs. Estimates